Under 10% of individuals eligible to benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it publishes its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for increased and just access to these injectable treatments.
According to projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our new guidance recognises that excess weight is a chronic disease that can be managed with comprehensive and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key barriers to widespread availability to the jabs that can aid individuals in losing considerable body mass, says the agency.
Skinny Jab Shortage
Even under the current most favorable scenario, the manufacturing of these medications might only reach around 100 million people – under 10% of eligible patients, as stated by the health organization.
The guideline calls on nations and manufacturers to expand access, through strategies such as licensing agreements.
A patent on a key compound – the primary component of a leading brand – is set to lapse in multiple countries in 2026.
How Weight-Loss Drugs Operate
The injections replicate a body's own hormone to slow digestion, suppress the appetite and enhance the sense of being full so users reduce food intake.
Patients usually start to lose weight in the initial weeks of commencing the weekly injections.
Studies suggests users may put most of the weight back on within a year of halting the drug, when their usual food cravings return.
Being above a healthy weight increases your chance for developing health problems, including type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity affects individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.
